Skip to Content

Abbott Laboratories - Stock Quote ABT

Rating as of

Morningstar's Abbott Laboratories Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Abbott Benefits From Omicron Surge, but COVID-19 Could Turn to Headwind in 2022

Debbie S. Wang Senior Equity Analyst

Business Strategy and Outlook

| Debbie S. Wang |

Since 2013, Abbott has continued to improve the profitability of its four segments: nutritionals, devices, diagnostics, and established pharmaceuticals. Although the company has made progress over the last nine years, it still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - ABT

Abbott Laboratories's Company Profile

Business Description

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Contact
100 Abbott Park Road
Abbott Park, IL, 60064-6400
T +1 224 667-6100
Industry Medical Devices
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 113,000

Abbott Laboratories's Related News